Ad
related to: fda indications for modafinil 5 mg
Search results
Results from the WOW.Com Content Network
Unlike modafinil, adrafinil does not have FDA approval and was withdrawn from the French market in 2011. [169] The FDA approved modafinil in 1998 for narcolepsy treatment, and later for shift work sleep disorder and obstructive sleep apnea in 2003. [8] [170] [171] It was approved in the UK in December 2002.
A Cephalon-founded study in which patients were administered modafinil, methylphenidate, and a placebo found that modafinil produces "psychoactive and euphoric effects and feelings consistent with [methylphenidate]." [12] Like modafinil, armodafinil is an inhibitor and/or inducer of certain cytochrome P450 enzymes.
Modafinil is a drug that helps keep people awake and alert (wakefulness-promoting agent or "eugeroic"). [ 1 ] [ 2 ] Most of the listed modafinil analogues are drugs that specifically target dopamine reuptake (reabsorption of a neurotransmitter by a neurotransmitter transporter ) with stronger effects ( selective DRIs with improved potency ...
For premium support please call: 800-290-4726 more ways to reach us
In the United States military, modafinil has been approved for use on certain Air Force missions, and it is being investigated for other uses. [19] As of November 2012, modafinil is the only drug approved by the Air Force as a "go pill" for fatigue management. [20] The use of dextroamphetamine (a.k.a., Dexedrine) is no longer approved. [20] Yes ...
Eugeroics, in the sense of modafinil-type wakefulness promoting agents, include modafinil itself, armodafinil, and adrafinil, among others. [9] They are medically indicated for the treatment of certain sleep disorders , including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III. The complete list of Schedule IV substances is as follows.
Solriamfetol at higher-than-approved doses—specifically doses of 300, 600, and 1,200 mg, which are 2 to 4 times the maximum recommended dose—produces drug-liking responses, including elevated mood and feelings of relaxation, that are similar in degree to those of phentermine (a Schedule IV controlled substance). [1]
Ad
related to: fda indications for modafinil 5 mg